Article Text

Download PDFPDF

5PSQ-176 Discontinuation of etanercept due to adverse events in patients with rheumatic diseases
  1. C Pastor Mondéjar,
  2. C Iniesta Navalón,
  3. I Salar Valverde,
  4. AM Martínez Soto,
  5. P Ortíz Fernández,
  6. M Gil Candel,
  7. M Onteniente Candela,
  8. A Quesada Asencio,
  9. MDC Caballero Requejo,
  10. L Rentero Redondo,
  11. E Urbieta Sanz
  1. Reina Sofia General University Hospital, Hospital Pharmacy, Murcia, Spain


Background and importance Etanercept is a fusion protein composed of the p75 receptor of tumour necrosis factor (TNF) and the Fc portion of human immunoglobulin. It is indicated for the treatment of diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis as its mechanism of action is blocking TNF.

Aim and objectives The aim of this study was to analyse the causes of treatment discontinuation due to adverse events.

Material and methods A retrospective study was performed in which all patients diagnosed with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis treated with etanercept at some point (between 2007 and 2016) were included. Data for etanercept’s dispensations, causes of treatment discontinuation, sex and age of the patients were collected. We used Excel to analyse the data.

Results 85 patients diagnosed with rheumatoid arthritis, 59 with ankylosing spondylitis and 44 with psoriatic arthritis treated with etanercept were included. 76.47%, 45% and 54.8% were women, with an average age of 58.2 (±13.6), 41.1 (±11.3), 55.3 (±13.1) in the rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis groups, respectively. 132 patients (70%) discontinued treatment with etanercept for different reasons. The main cause was adverse events, representing 28% of the total. Other causes were: secondary failure (27%), primary failure (22%), patient’s reasons (5%) and remission (4%). Among the adverse events, about 50% were dermatological: 27.8% related to the injection site, 22.2% skin reactions and 44.4% due to hypersensitivity. Other causes were infection (21.6%), diarrhoea (5.4%) and neutropenia (2.7%), among others.

Conclusion and relevance Etanercept is the most commonly used anti-TNF biological drug to treat rheumatological diseases. Among the different reasons for treatment discontinuation with etanercept, adverse effects was the main cause (28%). Allergic reactions or skin reactions were the most common adverse events.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.